D C Talbot - Concepedia

Author

D C Talbot

Churchill Hospital

Also Known As

D C Talbot, D Talbot, D. C. Talbot, D. Talbot, D.C Talbot, D.C. TALBOT, D.C. Talbot, DENIS C. TALBOT

Publications

Citations

H-Index

Concepts

All Affiliations

Churchill Hospital University of Oxford Cancer Research UK Beatson West of Scotland Cancer Centre Royal Marsden Hospital

About

D C Talbot is an author at Churchill Hospital specializing in medicine, radiation oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	548
2	Health Sciences	3	3	65
3	Education	1	1	47
4	Nursing	1	1	47
5	Accounting	1	1	47

D C Talbot

Publications

898

Citations

H-Index

Page 1

	Year	Citations
PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER Alexandra Giatromanolaki, Michael Koukourakis, Kenneth J. O’Byrne, The Journal of Pathology	1996	170
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Valentine M. Macaulay, Kenneth J. O’Byrne, Mark Saunders, PubMed Intrapleural Bb-94Matrix Metalloproteinase InhibitorIntrapleural AdministrationImmunologyPathology	1999	160
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. N C Levitt, Ferry A.L.M. Eskens, Kenneth J. O’Byrne, PubMed Tumor ResponseChemoprevention StrategyPharmacological StudyMedicinePharmacology	2001	136
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. D C Talbot, Ian E. Smith, Janine Mansi, Journal of Clinical Oncology World Health OrganizationBreast OncologyCancer ManagementActive New AgentPharmacotherapy	1991	62
Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. W.P. Steward, Dunlop Dj, G Dabouis, PubMed	1996	58
The development of a structured rating schedule (the BAS) to assess skills in breaking bad news S J Miller, Tony Hope, D C Talbot British Journal of Cancer EducationMedia StudiesJournalismProgram EvaluationInteractive Journalism	1999	47
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study William P. Steward, Mark R. Middleton, A. Benghiat, Annals of Oncology Translational MedicinePharmacodynamic End PointsPharmacologyRadiopharmaceutical TherapyPharmacotherapy	2007	43
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours Louise Medley, Alain Morel, David Farrugia, British Journal of Cancer	2011	35
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer Omar Khan, Andrew D. Blann, Miranda Payne, British Journal of Cancer	2011	34
Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000 David Propper, Johann S. de Bono, Azeem Saleem, Journal of Clinical Oncology	2003	33

Page 1